“Celldex made important progress across our pipeline in the fourth quarter, continuing to execute on our ongoing CDX-1140 and CDX-3379 clinical programs and advancing earlier stage assets that we believe have the potential to play an important role in the future of the organization,” said
“Data from both the CDX-1140 and MerTK programs were presented at
Recent Highlights:
- Enrollment continues in the Phase 1 dose-escalation study of CDX-1140 with recurrent, locally advanced or metastatic solid tumors and B cell lymphomas. CD40 has long been an important target for immunotherapy, as it plays a critical role in the activation of innate and adaptive immune responses; however, effectively balancing systemic dosing and safety has proven challenging to date for CD40-activating therapeutics. CDX-1140 is a unique, potent CD40 agonist that Celldex believes has the potential to successfully balance systemic doses for good tissue and tumor penetration with an acceptable safety profile. Interim data from the ongoing study have been accepted for presentation on
Tuesday, April 2, 2019 at theAmerican Association for Cancer Research (AACR) Annual Meeting.
- Data to date from the six completed dosing cohorts (0.01, 0.03, 0.09, 0.18, 0.36 and 0.72 mg/kg) suggest that CDX-1140 is exhibiting a desirable safety profile and demonstrating clear signs of biological activity based on biomarker analysis. The seventh monotherapy cohort at 1.5 mg/kg is currently being enrolled, along with the combination therapy cohort of CDX-1140 (0.18 mg/kg) with CDX-301. CDX-301 is a dendritic cell growth factor being utilized as a priming agent to increase the number of cells available to respond to CDX-1140. In addition, Celldex is evaluating the potential for combination with varlilumab, especially in lymphomas which co-express CD40 and CD27 receptors.
- Early data from the Phase 1 study were presented in
November 2018 at theSociety for Immunotherapy of Cancer (SITC ) Annual Meeting. Dose dependent biological effects consistent with CD40-mediated immune activation were reported; CDX-1140 was well tolerated and no MTD had been reached.
- Data to date from the six completed dosing cohorts (0.01, 0.03, 0.09, 0.18, 0.36 and 0.72 mg/kg) suggest that CDX-1140 is exhibiting a desirable safety profile and demonstrating clear signs of biological activity based on biomarker analysis. The seventh monotherapy cohort at 1.5 mg/kg is currently being enrolled, along with the combination therapy cohort of CDX-1140 (0.18 mg/kg) with CDX-301. CDX-301 is a dendritic cell growth factor being utilized as a priming agent to increase the number of cells available to respond to CDX-1140. In addition, Celldex is evaluating the potential for combination with varlilumab, especially in lymphomas which co-express CD40 and CD27 receptors.
- Enrollment is complete in the first stage of the Phase 2 study (n=13) of CDX-3379 in advanced head and neck squamous cell cancer in combination with Erbitux® in Erbitux-resistant patients who have been previously treated with or are ineligible for checkpoint therapy. According to the study’s Simon two-stage design, if at least one patient achieves an objective response in the first stage, enrollment may progress to the second stage. While a confirmed complete response has been documented, Celldex will conduct a comprehensive review, including the full data set, before making decisions on future development, as patients are still undergoing treatment and are eligible for evaluation. Celldex plans to present updated data from the study at a future medical meeting in 2019.
- Celldex continues to advance a robust preclinical portfolio. Data from the Company’s MerTK antibody program were presented in
November 2018 at the SITC Annual Meeting and have been accepted for presentation at the AACR meeting onMonday, April 1, 2019 . MerTK is emerging as a promising target for cancer immunotherapy; its expression in innate immune cells is believed to negatively regulate immune responses and genetic removal of MerTK renders mice resistant to some tumors. Data from the Company’s bispecific program, CDX-527, have also been accepted for presentation at AACR onMonday, April 1, 2019 . CDX-527 uses Celldex’s proprietary highly active anti-PD-L1 and CD27 human antibodies to couple CD27 co-stimulation with blockade of the PD-L1/PD-1 pathway.
Fourth Quarter and Twelve Months 2018 Financial Highlights and 2019 Guidance
NASDAQ Compliance: Celldex completed a one for fifteen reverse stock split, which became effective
Cash Position: Cash, cash equivalents and marketable securities as of
Revenues: Total revenue was
R&D Expenses: Research and development (R&D) expenses were
G&A Expenses: General and administrative (G&A) expenses were
Intangible Asset and Goodwill Impairments: During the year ended
Changes in Fair Value Remeasurement of Contingent Consideration: During the year ended
Net Loss: Net loss was
Financial Guidance: Celldex believes that the cash, cash equivalents and marketable securities at December 31, 2018, combined with the anticipated proceeds from future sales of common stock under the Cantor agreement, are sufficient to meet estimated working capital requirements and fund planned operations through 2020. This could be impacted if Celldex elects to pay Kolltan contingent milestones, if any, in cash.
Webcast and Conference Call
Celldex executives will host a conference call at
A replay of the call will be available approximately two hours after the live call concludes through
Erbitux® is a registered trademark of
About
Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. Our pipeline includes immunotherapies and other targeted biologics derived from a broad set of complementary technologies which have the ability to engage the human immune system and/or directly inhibit tumors to treat specific types of cancer or other diseases. Visit www.celldex.com.
Forward Looking Statement
This release contains "forward-looking statements" made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as "believes," "expects," "anticipates," "intends," "will," "may," "should," or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates; our ability to obtain additional capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; our ability to maintain compliance with Nasdaq listing requirements; our ability to realize the anticipated benefits from the acquisition of Kolltan; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical and commercial grade materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; and other factors listed under "Risk Factors" in our annual report on Form 10-K and quarterly reports on Form 10-Q.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise.
Company Contact
Senior Vice President, Corporate Affairs & Administration
(781) 433-3161
scavanaugh@celldex.com
| CELLDEX THERAPEUTICS, INC. | |||||||||||||||||
| (In thousands, except per share amounts) | |||||||||||||||||
| CONSOLIDATED STATEMENTS | Three Months | Year | |||||||||||||||
| OF OPERATIONS DATA | Ended December 31, | Ended December 31, | |||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| (Unaudited) | |||||||||||||||||
| REVENUES: | |||||||||||||||||
| Product Development and | |||||||||||||||||
| Licensing Agreements | $ | 549 | $ | 665 | $ | 3,341 | $ | 3,153 | |||||||||
| Contracts and Grants | 1,215 | 2,791 | 6,197 | 9,590 | |||||||||||||
| Total Revenue | 1,764 | 3,456 | 9,538 | 12,743 | |||||||||||||
| OPERATING EXPENSES: | |||||||||||||||||
| Research and Development | 11,207 | 23,464 | 66,449 | 96,171 | |||||||||||||
| General and Administrative | 4,332 | 5,894 | 19,269 | 25,003 | |||||||||||||
| Goodwill Impairment | - | - | 90,976 | - | |||||||||||||
| Intangible Asset Impairment | - | - | 18,677 | 13,000 | |||||||||||||
| Gain on Fair Value Remeasurement | |||||||||||||||||
| of Contingent Consideration | (1,653 | ) | (600 | ) | (29,621 | ) | (800 | ) | |||||||||
| Amortization of Acquired Intangible Assets | - | 224 | 224 | 896 | |||||||||||||
| Total Operating Expense | 13,886 | 28,982 | 165,974 | 134,270 | |||||||||||||
| Operating Loss | (12,122 | ) | (25,526 | ) | (156,436 | ) | (121,527 | ) | |||||||||
| Investment and Other Income, Net | 2,720 | 2,603 | 4,487 | 4,214 | |||||||||||||
| Net Loss Before Income Tax Benefit | (9,402 | ) | (22,923 | ) | (151,949 | ) | (117,313 | ) | |||||||||
| Income Tax Benefit | - | 19,082 | 765 | 24,282 | |||||||||||||
| Net Loss | $ | (9,402 | ) | $ | (3,841 | ) | $ | (151,184 | ) | $ | (93,031 | ) | |||||
| Basic and Diluted Net Loss per | |||||||||||||||||
| Common Share | $ | (0.81 | ) | $ | (0.42 | ) | $ | (14.48 | ) | $ | (10.86 | ) | |||||
| Shares Used in Calculating Basic | |||||||||||||||||
| and Diluted Net Loss per Share | 11,626 | 9,101 | 10,442 | 8,570 | |||||||||||||
| (Reflects one for fifteen reverse stock split effective February 8, 2019) | |||||||||||||||||
| CONDENSED CONSOLIDATED | |||||||||||||||||
| BALANCE SHEETS DATA | December 31, | December 31, | |||||||||||||||
| 2018 | 2017 | ||||||||||||||||
| ASSETS | |||||||||||||||||
| Cash, Cash Equivalents and Marketable Securities | $ | 94,022 | $ | 139,427 | |||||||||||||
| Other Current Assets | 5,057 | 5,329 | |||||||||||||||
| Property and Equipment, net | 6,111 | 10,372 | |||||||||||||||
| Intangible and Other Assets, net | 50,619 | 160,496 | |||||||||||||||
| Total Assets | $ | 155,809 | $ | 315,624 | |||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | |||||||||||||||||
| Current Liabilities | $ | 12,602 | $ | 27,736 | |||||||||||||
| Long-Term Liabilities | 19,147 | 51,519 | |||||||||||||||
| Stockholders' Equity | 124,060 | 236,369 | |||||||||||||||
| Total Liabilities and Stockholders' Equity | $ | 155,809 | $ | 315,624 | |||||||||||||
Source: Celldex Therapeutics, Inc.